bluuebunny/crossref_metadata_2025_split huggingface dataset:
Psychiatric history does not predict seizure outcome following temporal lobectomy for mesial temporal sclerosis
Authors: Adams Sophia J. , Velakoulis Dennis , Kaye Andrew H. , Corcoran Niall M. , O’Brien Terence J. 
Published: June 2012

SummaryPurpose:  A lifetime psychiatric history has been reported to be associated with poorer seizure outcome following temporal lobectomy for drug‐resistant focal epilepsy, but it remains unclear whether this is confounded by the nature of the epileptogenic pathology. Here we examined this association in a pathologically homogeneous group of patients with mesial temporal sclerosis (MTS).Methods:  The study population included 72 consecutive patients who underwent a temporal lobectomy for drug resistant temporal lobe epilepsy (TLE) and had histopathologically proven MTS. All patients were assessed preoperatively by a neuropsychiatrist. Chi‐square analysis was undertaken to look for demographic, clinical, psychiatric, or neurologic factors associated with seizure outcome at 1 year. The relationship between having a psychiatric disorder and seizure outcome was examined by generating Kaplan‐Meier curves and comparing between groups the log rank test as well as generating Cox regression models to estimate hazard ratios.Key Findings:  There were no significant associations between postsurgery seizure outcome and a current or lifetime history of any psychiatric disorder.Significance:  A history of psychiatric disorder, in particular depression and psychosis, is not associated with a poorer surgical outcome in patients with MTS. These findings have implications for the clinical management of patients under consideration for temporal lobectomy.
Deficiencies in Patients’ Comprehension of Implantable Cardioverter Defibrillator Therapy
Authors: GROARKE JOHN , BEIRNE AVRIL , BUCKLEY UNA , O’DWYER ELISABETH , SUGRUE DECLAN , KEELAN TED , O’NEILL JAMES , GALVIN JOE , MAHON NIALL 
Published: June 2012

Background: Patients receive education before implantable cardioverter defibrillator (ICD) implantation. Patients’ understanding of ICD therapy requires investigation.
Methods: A retrospective cohort study was carried out at two implant centers where patients are educated during a consenting process pre‐ICD implantation. Questionnaires examining understanding of ICD therapy were completed during telephone interviews of patients with ICDs.
Results: Of 75 patients interviewed, 62 (83%) were male. The median age at time of ICD implantation was 64 years (standard deviation [SD] = 9.4; range: 29–82 years). The median interval from implantation to interview was 3 years (SD = 1.9; range: 0.1–9.0 years). Despite 83% (62 of 75) claiming to understand the reason for ICD implantation, no patient suggested arrhythmia termination when describing the indication.Of shock recipients, 60% (12 of 20) felt poorly prepared for shock therapy. Of patients who experienced a device‐related complication, 83% (10 of 12) reported feeling inadequately forewarned of complications. Excluding patients with cardiac resynchronization therapy defibrillators (n = 6), 65% (45 of 69), 52% (36 of 69), 50% (35 of 69), and 61% (42 of 69) believe their ICD reduces risk of heart attack and improves breathing, exercise capacity, and heart function, respectively. Ninety‐three percent (70 of 75) are satisfied with their decision to accept ICD therapy. Only 12% (9 of 75) believe they will want to inactivate therapies in setting of terminal illness.
Conclusions:
Despite preimplantation education, patient comprehension of the risks and benefits of ICD therapy is poor. Patients’ expectations of ICD therapy may be inappropriate. Education strategies before and after implantation require improvement. (PACE 2012; 35:1097–1102)
Myocardium of the Superior Vena Cava, Coronary Sinus, Vein of Marshall, and the Pulmonary Vein Ostia: Gross Anatomic Studies in 620 Hearts
Authors: DESIMONE CHRISTOPHER V. , NOHERIA AMIT , LACHMAN NIRUSHA , EDWARDS WILLIAM D. , GAMI APOOR S. , MALESZEWSKI JOSEPH J. , FRIEDMAN PAUL A. , MUNGER THOMAS M. , HAMMILL STEPHEN C. , PACKER DOUGLAS L. , ASIRVATHAM SAMUEL J. 
Published: June 2012

Anatomy of Myocardial Extensions in Thoracic Veins.Introduction: Radiofrequency ablation for atrial fibrillation (AF) frequently involves energy delivery at the ostia of the thoracic veins. Detailed evaluation of the myocardium extending into the caval veins, vein of Marshall, as well as at the pulmonary vein ostia has not been completely evaluated.Methods and Results: Post‐mortem assessment of 620 formalin‐fixed hearts (mean age 60 ± 23 years, 44% female) was performed. The hearts were examined for integrity of venous structures and their atrial connections. Systematic gross anatomic evaluation including measurements on myocardial extensions in these veins was performed. Macroscopic myocardial extensions into pulmonary veins were noted in 99% of specimens evaluated and were circumferentially symmetric (99.6%). Myocardial extensions into the superior vena cava (SVC) occurred in 78% with the majority being circumferentially asymmetric (61%). Occasionally, myocardium extended into the azygos vein (6%). There were no myocardial extensions in the inferior vena cava (IVC). In some cases, the right atrial pectinate muscle extended into the coronary sinus (7%). The vein of Marshall was consistently located anterior to the left‐sided pulmonary veins and posterior to the left atrial appendage, overlying the left atrial endocardial ridge.Conclusions: Myocardial extensions into the pulmonary veins are usually circumferential at the ostia validating the necessity for wide area rather than segmental ablation to isolate these veins during AF ablation. Myocardial extensions into the SVC are common and less likely to be circumferential, whereas extensions into the IVC are not present. The left atrial ridge is a reliable endocardial target for radiofrequency ablation of the vein of Marshall. (J Cardiovasc Electrophysiol, Vol. 23, pp. 1304‐1309, December 2012)
Microvascular Repair: Post‐Angiogenesis Vascular Dynamics
Authors: LEBLANC AMANDA J. , KRISHNAN LAXMINARAYANAN , SULLIVAN CHRISTOPHER J. , WILLIAMS STUART K. , HOYING JAMES B. 
Published: June 2012

Please cite this paper as: LeBlanc AJ, Krishnan L, Sullivan CJ, Williams SK, Hoying JB. Microvascular repair: post‐angiogenesis vascular dynamics. Microcirculation19: 676–695, 2012.AbstractVascular compromise and the accompanying perfusion deficits cause or complicate a large array of disease conditions and treatment failures. This has prompted the exploration of therapeutic strategies to repair or regenerate vasculatures, thereby establishing more competent microcirculatory beds. Growing evidence indicates that an increase in vessel numbers within a tissue does not necessarily promote an increase in tissue perfusion. Effective regeneration of a microcirculation entails the integration of new stable microvessel segments into the network via neovascularization. Beginning with angiogenesis, neovascularization entails an integrated series of vascular activities leading to the formation of a new mature microcirculation, and includes vascular guidance and inosculation, vessel maturation, pruning, AV specification, network patterning, structural adaptation, intussusception, and microvascular stabilization. While the generation of new vessel segments is necessary to expand a network, without the concomitant neovessel remodeling and adaptation processes intrinsic to microvascular network formation, these additional vessel segments give rise to a dysfunctional microcirculation. While many of the mechanisms regulating angiogenesis have been detailed, a thorough understanding of the mechanisms driving post‐angiogenesis activities specific to neovascularization has yet to be fully realized, but is necessary to develop effective therapeutic strategies for repairing compromised microcirculations as a means to treat disease.
Bars in hydrodynamical cosmological simulations
Authors: Scannapieco Cecilia , Athanassoula E. 
Published: June 2012

Abstract
We study the properties of two bars formed in fully cosmological hydrodynamical simulations of the formation of Milky Way-mass galaxies. In one case, the bar formed in a system with disc, bulge and halo components, and is relatively strong and long, as could be expected for a system where the spheroid strongly influences the evolution. The second bar is less strong, shorter and formed in a galaxy with no significant bulge component. We study the strength and length of the bars, the stellar density profiles along and across the bars, and the velocity fields in the bar region. We compare them with the results of dynamical (idealized) simulations and with observations, and find, in general, a good agreement, although we detect some important differences as well. Our results show that more or less realistic bars can form naturally in a Λ cold dark matter cosmology, and open up the possibility to study the bar formation process in a more consistent way than previously done, since the host galaxies grow, accrete matter and significantly evolve during the formation and evolution of the bar.
Assessment of stakeholders’ preferences towards sustainable sanitation scenarios
Authors: Bao Pham Ngoc , Aramaki Toshiya , Hanaki Keisuke 
Published: June 2012

AbstractDecision making in sanitation planning is often complex, with inherent trade‐offs among sociopolitical, environmental, technical and economic factors. The selection of appropriate and sustainable sanitation systems for municipal wastewater treatment involves multiple criteria with conflicting stakeholder preferences. To fulfil conflicting yet complementary objectives, one of the best known and most widely used multi‐criteria analysis (MCA) approaches called the Analytic Hierarchy Process (AHP) has been employed as a decision support tool to aid decision makers in sanitation planning process in developing countries. AHP, in combination with life cycle assessment (LCA) and a proposed set of multidimensional criteria, has worked as an effective decision support tool for the sustainability assessment and selection of appropriate wastewater treatment system with a capacity of 1200 m3/day, in a case study in Toan Thang, a small town in Vietnam. Results from this case study have indicated that the public's understanding of trade‐offs is critical in gaining public support for long‐term sustainability of the solution. The findings from this study have also shown AHP as an effective and flexible communication tool for group decision making in sanitation planning.
Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase Inhibitors
Authors: Asahchop Eugene L. , Wainberg Mark A. , Sloan Richard D. , Tremblay Cécile L. 
Published: June 2012

ABSTRACTHighly active antiretroviral therapy (HAART) consists of a combination of drugs to achieve maximal virological response and reduce the potential for the emergence of antiviral resistance. Despite being the first antivirals described to be effective against HIV, reverse transcriptase inhibitors remain the cornerstone of HAART. There are two broad classes of reverse transcriptase inhibitor, the nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). Since the first such compounds were developed, viral resistance to them has inevitably been described; this necessitates the continuous development of novel compounds within each class. In this review, we consider the NRTIs and NNRTIs currently in both preclinical and clinical development or approved for second-line therapy and describe the patterns of resistance associated with their use as well as the underlying mechanisms that have been described. Due to reasons of both affordability and availability, some reverse transcriptase inhibitors with a low genetic barrier are more commonly used in resource-limited settings. Their use results in the emergence of specific patterns of antiviral resistance and so may require specific actions to preserve therapeutic options for patients in such settings.
Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome
mec
Types
Authors: Castanheira Mariana , Sader Helio S. , Farrell David J. , Mendes Rodrigo E. , Jones Ronald N. 
Published: June 2012

ABSTRACT

Ceftaroline is a new cephalosporin with broad-spectrum activity against Gram-positive and -negative organisms. The prodrug of ceftaroline, ceftaroline fosamil, combined with the β-lactamase inhibitor avibactam (formerly NXL104), was tested against
Enterobacteriaceae
strains producing Ambler class A, B, C, and D enzymes, including strains producing multiple enzymes, as well as
Pseudomonas aeruginosa
,
Acinetobacter
spp., and methicillin-susceptible and methicillin-resistant
Staphylococcus aureus
(MRSA) strains. Isolates were collected from 1999 to 2008 from global surveillance programs, and susceptibility testing was performed by reference broth microdilution methods. Ceftaroline-avibactam exhibited potent activity against
Enterobacteriaceae
producing various β-lactamase types (MIC
90
, 0.25 to 2 μg/ml, except for metalloenzymes), including 99 strains carrying multiple enzymes (2 to 4 β-lactamases; MIC
90
, 2 μg/ml). All isolates were inhibited by ceftaroline-avibactam at ≤4 μg/ml. Ceftaroline-avibactam (MIC
90
, 0.5 to 1 μg/ml) was more active than meropenem (MIC
90
, >8 μg/ml) and other comparators when tested against KPC-producing strains.
S. aureus
strains, including MRSA with four staphylococcal cassette chromosome
mec
(SCC
mec
) types, were dominantly (99.1%) inhibited by ceftaroline-avibactam at ≤2 μg/ml, and the ceftaroline MIC was not adversely affected by the addition of the β-lactamase inhibitor (MIC
50/90
, 1 and 2 μg/ml for ceftaroline with and without avibactam). Ceftaroline-avibactam demonstrated limited activity against
Acinetobacter
spp. and
P. aeruginosa
(MIC
50
s, 32 and 16 μg/ml, respectively). These results document that ceftaroline-avibactam has potent activity against
Enterobacteriaceae
that produce KPC, various ESBL types (CTX-M types), and AmpC (chromosomally derepressed or plasmid-mediated enzymes), as well as against those producing more than one of these β-lactamase types, and its development as a therapeutic option for the treatment of infections caused by multidrug-resistant
Enterobacteriaceae
as well as MRSA is warranted.
Draft Genome Sequence of Pseudomonas syringae Pathovar Syringae Strain FF5, Causal Agent of Stem Tip Dieback Disease on Ornamental Pear
Authors: Sohn Kee Hoon , Jones Jonathan D. G. , Studholme David J. 
Published: June 2012

ABSTRACTPseudomonas syringaeFF5 causes stem tip dieback disease on ornamental pear (Pyrus calleryana). Its genome encodes a complete type III secretion system (T3SS) and HopAC1, HopM1, AvrE1, HopI1, HopAA1, HopJ1, HopAH2, HopAH1, HopAG1, and HopAZ1. Lacking detectable homologues of other T3SS effectors, it may encode novel, undiscovered effectors.
Draft Genome Sequence of Pedobacter agri PB92
T
, Which Belongs to the Family Sphingobacteriaceae
Authors: Lee Myunglip , Roh Seong Woon , Lee Hae-Won , Yim Kyung June , Kim Kil-Nam , Bae Jin-Woo , Choi Kwang-Sik , Jeon You-Jin , Jung Won-Kyo , Kang Heewan , Hyun Chang-Gu , Kim Daekyung 
Published: June 2012

ABSTRACT

Strain PB92
T
of
Pedobacter agri
, which belongs to the family
Sphingobacteriaceae
, was isolated from soil in the Republic of Korea. The draft genome of strain PB92
T
contains 5,141,552 bp, with a G+C content of 38.0%. This is the third genome sequencing project of the type strains among the
Pedobacter
species.
Draft Genome Sequence of Gillisia sp. Strain CBA3202, a Novel Member of the Genus Gillisia, Which Belongs to the Family Flavobacteriaceae
Authors: Nam Young-Do , Lee Hae-Won , Lee Myunglip , Yim Kyung June , Kim Kil-Nam , Roh Seong Woon , Kim Daekyung 
Published: June 2012

ABSTRACT

Gillisia
sp. strain CBA3202, which belongs to the family
Flavobacteriaceae
, was isolated from sand of the seashore on Jeju Island, Republic of Korea. The draft genome of
Gillisia
sp. CBA3202 contains 2,981,404 bp with a G+C content of 34.9%. This is the second genome sequence of the
Gillisia
strains.
Genome Sequence of the Marine Bacterium Marinilabilia salmonicolor JCM 21150
T
Authors: Kumar Shailesh , Subramanian Srikrishna , Raghava Gajendra Pal Singh , Pinnaka Anil Kumar 
Published: June 2012

ABSTRACT

We report the 4.98-Mb genome sequence of
Marinilabilia salmonicolor
JCM 21150
T
, which was isolated from marine mud in the year 1961. The draft genome of strain
Marinilabilia salmonicolor
JCM 21150
T
contains 4,982,627 bp with a G+C content of 41.92% and 4,227 protein coding genes, 52 tRNAs, and 3 rRNAs.
Draft Genome of Streptomyces tsukubaensis NRRL 18488, the Producer of the Clinically Important Immunosuppressant Tacrolimus (FK506)
Authors: Barreiro Carlos , Prieto Carlos , Sola-Landa Alberto , Solera Elena , Martínez-Castro Miriam , Pérez-Redondo Rosario , García-Estrada Carlos , Aparicio Jesús F. , Fernández-Martínez Lorena T. , Santos-Aberturas Javier , Salehi-Najafabadi Zahra , Rodríguez-García Antonio , Tauch Andreas , Martín Juan F. 
Published: June 2012

ABSTRACT

The macrocyclic polyketide tacrolimus (FK506) is a potent immunosuppressant that prevents T-cell proliferation produced solely by
Streptomyces
species. We report here the first draft genome sequence of a true FK506 producer,
Streptomyces tsukubaensis
NRRL 18488, the first tacrolimus-producing strain that was isolated and that contains the full tacrolimus biosynthesis gene cluster.
Dose‐response investigation of oral ketoprofen in pigs challenged with Escherichia coli endotoxin
Authors: Mustonen K. , Banting A. , Raekallio M. , Heinonen M. , Peltoniemi O. A. T. , Vainio O. 
Published: June 2012

In order to determine the effective dose, the effects of orally administered ketoprofen were evaluated in pigs following intravenous challenge with Escherichia coli endotoxin. One hour after the challenge, five groups of pigs were treated with either tap water or ketoprofen (0.5 mg/kg, 1 mg/kg, 2 mg/kg or 4 mg/kg). The body temperature was measured and a total clinical score was calculated after assessing the general behaviour, respiratory rate and locomotion of the pigs. Thromboxane B2 and ketoprofen concentrations were analysed from blood samples. Ketoprofen treatment significantly reduced the rectal temperature and total clinical scores, and lowered blood thromboxane B2 concentrations when compared with the control group. Ketoprofen plasma concentrations were lower than previously reported in healthy pigs after similar doses. The appropriate dose of orally administered ketoprofen in pigs in this model is 2 mg/kg, as the higher dose of 4 mg/kg failed to provide an additional benefit.
Gaseous CO2 signal initiates growth of butyric-acid-producing Clostridium butyricum in both pure culture and mixed cultures with Lactobacillus brevis
Authors: Hakalehto Elias , Hänninen Osmo 
Published: June 2012

Microbial strains produce numerous volatile substances in the anaerobic conditions of the human intestines. The availability of CO2 is known to be a prerequisite for bacterial growth in general. In experiments with anaerobic Lactobacillus brevis and Clostridium butyricum bacteria in the Portable Microbial Enrichment Unit (PMEU) it was shown that these strains interact; this interaction being mediated by CO2 emission. CO2 promoted clostridial growth in pure cultures and mixed cultures with lactobacilli. The growth of C. butyricum in pure cultures was much delayed or did not start at all without CO2 from outside. Conversely, the onset of growth was provoked by a short (15 min) CO2 burst. In mixed cultures the presence of lactobacilli in equal numbers speeded up the onset of clostridial growth by 10 h. If C. butyricum cultures designated as PMEU 1, 2, and 3 in cultivation syringes were chained by connecting the gas flow thereby allowing the volatiles of the preceding syringe culture to bubble to the next one, the growth started in 20, 10, or 6 h, respectively. This effect of gaseous emissions from other cultures speeding up the bacterial growth initiation was abolished if the gas was passed through sodium hydroxide to remove the CO2. The positive contribution of lactobacilli to the growth of butyric-acid-producing clostridia documented in this simulation experiment with PMEU has in vivo implications and indicates molecular communication between the species. CO2 is a necessary signal for the growth of clostridia, and lactobacilli can promote clostridial growth in mixed cultures where both bacteria grow well with mutual benefit.
P1-12-07: Pharmacokinetics (PK) of Trastuzumab Emtansine and Paclitaxel or Docetaxel in Patients with HER2−Positive MBC Previously Treated with a Trastuzumab-Containing Regimen.
Authors: Lu D , Modi S , Elias AD , Agarwal P , Yi J-H , Guardino AE , Althaus BL , Girish S 
Published: June 2012

Abstract
Background: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate composed of trastuzumab, DM1 (a potent cytotoxic tubulin polymerization inhibitor), and the stable MCC linker. Based on in vitro and preclinical data suggesting synergy in tumor cell cytotoxicity with T-DM1 + taxanes, these combinations are being tested in phase Ib studies. The assessment of risk for PK-based drug interaction (PK-DI) with these combinations is important. T-DM1 is expected to undergo proteolytic degradation with no significant involvement of cytochrome P450 isoenzymes (CYPs), and DM1 is metabolized mainly by CYP3A4 (and to a lesser extent by CYP3A5). Paclitaxel (P) and docetaxel (D) are metabolized primarily by CYP2C8 and CYP3A4, respectively. None of these drugs inhibits or induces CYPs at clinically relevant concentrations. Since DM1 and D are both metabolized by CYP3A4, PK-DI may occur. This is less likely with DM1 and P since they are primarily metabolized by different CYPs.
Methods: The tolerability, PK, and dose-limiting toxicities of T-DM1 + P or D were investigated in 2 studies (TDM4652g and BP22572) of patients with HER2−positive MBC previously treated with a trastuzumab-containing regimen. For PK-DI analysis, both studies used a staggered dosing design in the first cycle, with same-day dosing in subsequent cycles. Study BP22572 was later amended to give both drugs on the same day in all cycles. Either P (65 mg/m2, n=11; 80 mg/m2, n=6) or D (60 mg/m2, n=12; 75 mg/m2, n=6) was combined with T-DM1 at various doses (2 mg/kg or 2.4 mg/kg q3w or 1.2 mg/kg qw for TDM4652g; 2.4 mg/kg or 3.6 mg/kg q3w for BP22572). PK of T-DM1, total trastuzumab (conjugated + unconjugated trastuzumab), DM1, P, and D were evaluated and compared with historical singleagent data and across cycles within the study, using population analysis and/or noncompartmental analysis (NCA), as data allowed. Preliminary safety and efficacy data for the historical T-DM1 singleagent studies were reported previously (Krop JCO 2010; Burris JCO 2010; Krop ESMO 2010).
Results: The PK of P and D were similar from cycle 1 to cycle 2 for maximum concentration (Cmax), area under the concentration-time curve, halflife, clearance (CL) and steady-state volume of distribution, and were also similar to historical single-agent data. The Cmax of DM1 was &lt;8 ng/mL in both studies, and the average Cmax values were similar to historical single-agent data. T-DM1 PK parameters for the combination studies are within the range of historical single-agent data (Table). Data from additional patients and doses in the combination studies will be presented.

Conclusion: The risk of clinically relevant PK-DI between T-DM1 and P or D appears to be low.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-12-07.